Ligand id: 7719

Name: osimertinib

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: osimertinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 87.55
Molecular weight 499.27
XLogP 3.44
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
A Phase III clinical trial (NCT02151981) is recruiting patients to compare AZD9291 vs. platinum-based doublet-chemotherapy in locally advanced or metastatic non-small cell lung cancer (Oct 2014). Click here to link to ClinicalTrials.gov's listing of AZD9291 trials. As a result of the FDA's accelerated approval program, osimertinib was approved in November 2015 for the treatment of patients with metastatic EGFRT790M mutation-positive NSCLC that has progressed on or after EGFR tyrosine kinase inhibitor therapy (and with the mutation confirmed using an FDA-approved test). This was converted to regular approval in March 2017. In April 2018 the FDA expanded osimertinib's approval to include use as a first-line treatment for metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations (again as detected by an FDA-approved test) [3].
External links